{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T06:09:14Z","timestamp":1795241354755,"version":"4.10.3"},"reference-count":31,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) includes patients with hepatic steatosis and at least one of five cardiometabolic risk factors. Xanthine oxidase (XO) represents a treatment target for MASLD. We aimed to evaluate the effect of two xanthine oxidase inhibitors, allopurinol and febuxostat, plus lifestyle modifications compared to lifestyle modifications alone on improving steatosis. Ninety MASLD patients were assigned to one of three groups for three months. Patients with hyperuricemia were given either allopurinol 100 mg or febuxostat 40 mg daily, along with lifestyle modifications. The third control group was only given lifestyle modifications, excluding all patients with hyperuricemia due to ethical concerns. The primary outcome was to measure the change in the controlled attenuation parameter (CAP) score as an indicator of steatosis from baseline after three months. The secondary outcome was to measure the change in serum uric acid (SUA) three months from baseline. The study found that the CAP score decreased significantly in the allopurinol group (p = 0.009), but the decline in the febuxostat or lifestyle groups was non-significant (p = 0.189 and 0.054, respectively). The SUA levels were significantly reduced in both the allopurinol and febuxostat groups (p &lt; 0.001), with no statistical difference between the two groups (p = 0.496).<\/jats:p>","DOI":"10.3390\/biomedicines11113074","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T07:11:27Z","timestamp":1700118687000},"page":"3074","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.3390","volume":"11","author":[{"given":"Amani","family":"Al-Shargi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 4393005, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4917-6392","authenticated-orcid":false,"given":"Amal A.","family":"El Kholy","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 4393005, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmoneim","family":"Adel","sequence":"additional","affiliation":[{"name":"National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo 4260010, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6001-8793","authenticated-orcid":false,"given":"Mohamed","family":"Hassany","sequence":"additional","affiliation":[{"name":"National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo 4260010, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Shaheen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 4393005, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000515445","article-title":"Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)","volume":"37","author":"Roeb","year":"2021","journal-title":"Visc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s43066-020-00043-x","article-title":"Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult","volume":"10","author":"Paul","year":"2020","journal-title":"Egypt. Liver J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cld.2017.08.004","article-title":"Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography","volume":"22","author":"Tsai","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_5","first-page":"e16414","article-title":"Estimation of Liver Fat by FibroScan in Patients with Nonalcoholic Fatty Liver Disease","volume":"13","author":"Shrestha","year":"2021","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/MEG.0000000000000931","article-title":"Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"29","author":"Jaruvongvanich","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"821689","DOI":"10.3389\/fendo.2022.821689","article-title":"A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"72110","DOI":"10.1136\/bmjopen-2023-072110","article-title":"Hyperuricaemia: Prevalence and association with mortality in an elderly Finnish population","volume":"13","author":"Timsans","year":"2023","journal-title":"BMJ Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1470380","DOI":"10.1155\/2021\/1470380","article-title":"The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors","volume":"2021","author":"Liu","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Abou-Rjeileh, U., and Contreras, G.A. (2021). Redox Regulation of Lipid Mobilization in Adipose Tissues. Antioxidants, 10.","DOI":"10.3390\/antiox10071090"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Guo, X., Yin, X., Liu, Z., and Wang, J. (2022). Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415489"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_13","first-page":"545","article-title":"The involvement and mechanism of febuxostat in non-alcoholic fatty liver disease cells","volume":"32","author":"Tang","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A comprehensive definition for metabolic syndrome","volume":"2","author":"Huang","year":"2009","journal-title":"Dis. Model Mech."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3904\/kjim.2017.343","article-title":"Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity","volume":"33","author":"Kwak","year":"2018","journal-title":"Korean J. Intern Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: Facts and figures","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0009-8981(80)90105-9","article-title":"IFCC methods for the measurement of catalytic concentrations of enzymes: Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2)","volume":"105","author":"Horder","year":"1980","journal-title":"Clin. Chim. Acta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zenovia, S., Stanciu, C., Sfarti, C., Singeap, A.-M., Cojocariu, C., Girleanu, I., Dimache, M., Chiriac, S., Muzica, C.M., and Nastasa, R. (2021). Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050787"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced Liver Fibrosis Is Common in Patients with Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3899\/jrheum.180761","article-title":"Hepatic safety of febuxostat compared with allopurinol in gout patients with fatty liver disease","volume":"46","author":"Lee","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7861\/clinmedicine.17-1-54","article-title":"Gout\u2014A guide for the general and acute physicians","volume":"17","author":"Abhishek","year":"2017","journal-title":"Clin. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jhep.2015.01.019","article-title":"Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds","volume":"62","author":"Xu","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Allameh, A., Niayesh-Mehr, R., Aliarab, A., Sebastiani, G., and Pantopoulos, K. (2023). Oxidative Stress in Liver Pathophysiology and Disease. Antioxidants, 12.","DOI":"10.3390\/antiox12091653"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"13282","DOI":"10.3390\/ijms140713282","article-title":"NS3 protease from hepatitis C virus: Biophysical studies on an intrinsically disordered protein domain","volume":"14","author":"Vega","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"G42","DOI":"10.1152\/ajpgi.00443.2014","article-title":"The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model","volume":"309","author":"Nakatsu","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41598-020-57784-3","article-title":"Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice","volume":"10","author":"Nishikawa","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12944-023-01846-8","article-title":"Association of serum uric acid with hepatic steatosis detected by controlled attenuation parameter in the United States population","volume":"22","author":"Feng","year":"2023","journal-title":"Lipids Health Dis."},{"key":"ref_31","unstructured":"(2023, May 27). LiverTox: Clinical and Research Information on Drug\u2014Induced Liver Injury, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/31643176\/."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/11\/3074\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:24:03Z","timestamp":1760131443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/11\/3074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["biomedicines11113074"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11113074","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}